Suchergebnisse - "Csőszi, Tibor"

PubPharm (53)

1

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

enthalten in: The New England journal of medicine | 2024

von Wu, Y. | Dziadziuszko, R. | Ahn, J. | +120

2

Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer : KEYNOTE-782

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2024

von Bar, J. | Esteban, E. | Rodríguez-Abreu, D. | +20

3

A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Vaishampayan, U. | Keessen, M. | Dreicer, R. | +11

4

Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011) : A Phase 3, Randomized, Double-Blind Trial

enthalten in: European urology | 2024

von Matsubara, N. | de Wit, R. | Balar, A. | +18

5

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

enthalten in: The New England journal of medicine | 2024

von Powles, T. | Valderrama, B. | Gupta, S. | +122

6

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer : The Phase III DUO-E Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Westin, S. | Moore, K. | Chon, H. | +128

7

Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007) : A Randomized, Double-Blind, Phase 3 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Yang, J. | Han, B. | De La Mora Jiménez, E. | +16

8

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859) : a multicentre, randomised, double-blind, phase 3 trial

enthalten in: The Lancet. Oncology | 2023

von Rha, S. | Oh, D. | Yañez, P. | +121

9

Patient-Reported Health-Related Quality of Life in KEYNOTE-604 : Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

enthalten in: JTO clinical and research reports | 2023

von Kim, H. | Awad, M. | Navarro, A. | +17

10

Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Pascual, J. | Gil-Gil, M. | Proszek, P. | +20

1
2
3
4
5
6
Nächster »
[6]